RxDoctor Payments Data

Jonathan Sarik, MD

Plastic and Reconstructive Surgery · Milford, DENPI 1013207117

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 24 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by AbbVie at 53.4% of the total. Reporting peaked in 2019 at $454 and has fallen 70.2% since, to $135 in 2025.

$1,190in general payments, 2019–2025

Across 24 payments — averaging $49.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$636
  • Endo Pharmaceuticals Inc.$131
  • Acelrx Pharmaceuticals, Inc.$104
  • Johnson & Johnson$94
  • Smith+Nephew$45
  • Integra Lifesciences Corporation$42
  • plus $138 from 7 others

What the payments were for

  • Food & beverage$1,190100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few plastic and reconstructive surgery providers in Delawareto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$161,861
Medicare patients
190
Services billed
595

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cephalexin62$374
Tramadol Hcl55$64
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen18$49

Paid to pharmacies, not to this prescriber.

Other plastic and reconstructive surgery in Milford

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →